Premium
Helicobacter pylori as a class I carcinogen: Physiopathology and management strategies
Author(s) -
Vogiatzi Paraskevi,
Cassone Marco,
Luzzi Ida,
Lucchetti Chiara,
Otvos Laszlo,
Giordano Antonio
Publication year - 2007
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.21375
Subject(s) - helicobacter pylori , cancer , medicine , antibiotics , presentation (obstetrics) , antibiotic resistance , pathophysiology , immunology , stomach , intensive care medicine , bioinformatics , biology , microbiology and biotechnology , surgery
The gram‐negative bacterium Helicobacter pylori is known as a persistent colonizer of the human stomach, and probably less known is that it is also involved in extraintestinal diseases. Public awareness of its contribution in the development of gastric cancer is less than 15 years old. The efficacy of the current therapies based on antibiotics against H. pylori has been limited by difficulties such as antibiotic resistance and recurrence. As a consequence, the development of promising vaccines was prompted as the best preventive measure. Unfortunately, so far vaccines failed the transition from animal models to human trials. This keynote presentation is to provide a bird's eye view of H . pylori ‐related gastric diseases, including gastric cancer, with a synthesis of the molecular mechanisms involved, and an exhaustive presentation and discussion of the current therapeutic guidelines and future strategies for prevention or therapy. J. Cell. Biochem. 102: 264–273, 2007. © 2007 Wiley‐Liss, Inc.